Clinical Audit Awareness Week 2025 – events & activities programme announced!

23 Apr 2025

We’re pleased to share the initial line-up of FREE events and resources taking place during Clinical Audit Awareness Week 2025 (#CAAW25, 2 – 6 June), run in collaboration with N-QI-CAN. As well as the return of the popular Lunch & Learn online events (where we will announce the winners of the 2025 Clinical Audit Heroes Awards), we also have several other exciting events and activities exploring key themes in clinical audit and quality improvement. Here’s what’s coming up (click the links below to register for webinars in advance):

Monday 2 June 2025

  • 10.00am: NEW video release on HQIP’s website – Improving sepsis care through clinical audit, with HQIP’s Chair Dr Celia Ingham Clark & Clinical Fellow Dr Ollie Burton
  • 12.30pm–1.30pm: Online Lunch & Learn – Patient Safety, hosted by NQICAN and featuring the Patient Safety award announcement (use this link to REGISTER IN ADVANCE)
  • 2.00pm–2.30pm: Live Q&A on HQIP’s X account – Balancing learning in clinical audit and quality improvement with patient safety, with HQIP’s Clinical Fellow, Dr Ollie Burton

Tuesday 3 June 2025

  • 10.00am: NEW video release on HQIP’s website – Real stories of Patient & Public Involvement (PPI), with HQIP’s Head of Patient Engagement, Kim Rezel, and members of HQIP’s Service User Network
  • 12.30pm–1.30pm: Online Lunch & Learn – Patient & Public Involvement (PPI), hosted by NQICAN with HQIP’s Head of Patient Engagement Kim Rezel, and featuring the PPI award announcement (use this link to REGISTER IN ADVANCE)
  • 2.00pm: NEW blog release on HQIP’s website – My Data, My Health (Patient engagement in data access), featuring patient members of HQIP’s Data Access Request Group

Wednesday 4 June 2025

  • 10.00am: NEW podcast release on HQIP’s website – Addressing healthcare inequalities through clinical audit, with Dr Aoife Molloy, Senior Clinical Advisor for Healthcare Inequalities Improvement, NHS England & Danny Keenan, HQIP Medical Director
  • 12.30pm–1.30pm: Online Lunch & Learn – Healthcare Inequalities, hosted by NQICAN with HQIP’s Professor Danny Keenan, and featuring the Healthcare Inequalities award announcement (use this link to REGISTER IN ADVANCE)
  • 1.45pm–2.30pm: Webinar and Q&A – Better cardiovascular care through data, with CVDPREVENT’s Dr. Peter Green, Liz Corteville & Dr Veena Raleigh (use this link to REGISTER IN ADVANCE)

Thursday 5 June 2025

  • 11.00am–12 noon: NHS IMPACT & HQIP webinar and Q&A on Healthcare Improvement, featuring NHS IMPACT’s Jody O’Brien (Collaboration and Partnerships Lead) & Amy Hodgkinson (Head of Deployment)
  • 12.30pm–1.30pm: Online Lunch & Learn – Influencing Change, hosted by NQICAN and featuring the Influencing Change award announcement (use this link to REGISTER IN ADVANCE)
  • 2.15pm–3.00pm: Webinar – Data-Driven Improvements in Maternity Care: A Regional Medical Director’s Perspective, with NHS England’s Dr Edward Morris CBE FRCOG & HQIP Associate Director Tina Strack (use this link to REGISTER IN ADVANCE)

Friday 6 June 2025

  • 10.00am–11.00am: Webinar – Clinical Audit Heroes Commendation Awards, with presentations by winning projects that 1) use NCAPOP data to drive healthcare improvements, and 2) communicate effectively (use this link to REGISTER IN ADVANCE)
  • 12.30pm–1.30pm: Online Lunch & Learn – Efficiencies, hosted by NQICAN and featuring the Efficiencies award announcement (use this link to REGISTER IN ADVANCE)
Remember, you can also support quality improvement in healthcare by organising your own events during Clinical Audit Awareness Week. Use our FREE toolkit of resources to support #CAAW25 activities in your organisation. Do keep a lookout for further announcements on speakers and activities on the dedicated #CAAW25 webpage; or follow HQIP and N-QI-CAN on X, and HQIP’s LinkedIn using the hashtag #CAAW25.

Clinical Audit Heroes Awards 2025 – now open!

10 Apr 2025

HQIP is thrilled to announce that the Clinical Audit Heroes Awards, part of Clinical Audit Awareness Week 2025 (#CAAW25, 2nd – 6th June), are officially NOW OPEN for nominations! Run in collaboration with the National Quality Improvement (incl. Clinical Audit) Network (NQICAN), these prestigious awards celebrate excellence in clinical audit and quality improvement across healthcare. This year, the awards recognise outstanding projects across five main categories: Additionally, two brand-new commendations have been introduced: the NCAPOP Commendation for projects using National Clinical Audit Patient Outcomes Programme (NCAPOP) data, and the Communicating for Impact Commendation for excellence in project communication. The winner(s) of each award will be announced during a series of #CAAW25 Lunch & Learn online events, running daily throughout 2nd– 6th June, from 12:30 – 1:30pm. These sessions will feature expert speakers discussing key themes on effectively utilising clinical audit to prevent patient harm, engage and inform patients and the public, improve healthcare inequalities, drive change, and make healthcare sustainable. You can register to attend these Lunch & Learn events by visiting the main #CAAW25 page. Entering the awards is quick and easy! Go to the Clinical Audit Heroes Awards page for details on the criteria, eligibility and online nomination forms for all awards. The deadline for nominations is Sunday 27th April 2025 (23:59). You can follow updates on the wider campaign on the dedicated Clinical Audit Awareness Week 2025 page, as well as on social media using #CAAW25.

New resources published in April 2025

10 Apr 2025

We are pleased to announce that the following new resources from HQIP-commissioned audits and programmes have been published. They include infographics, data and recommendations to support quality improvement:
  • Type 2 diabetes spotlight audit report – National Paediatric Diabetes Audit (NPDA) This report covers the care provided to children and young people (CYP) with Type 2 diabetes by paediatric diabetes units (PDUs) in England and Wales between 1 April 2023 and 31 March 2024.
  • Lung cancer 2023 patient cohort report – National Lung Cancer Audit (NLCA/NATCAN) This report covers the care received by people diagnosed with lung cancer in England and Wales during 2023. In addition to describing the patterns of care received, it focuses on the overall national figures, and incorporates cancer waiting times and genomics testing. It also contains five recommendations for improvement.

Further data

The following additional data have been released by HQIP-commissioned programmes:
  • Cancer – In addition to the above lung cancer output, the National Cancer Audit Collaborating Centre (NATCAN) also released quarterly updated performance indicators for all ten cancer audits, via interactive dashboards. Find out more here.
  • Stroke – The Sentinel Stroke National Audit Programme (SSNAP) quarterly report covering data for Oct – Dec 2024 has been published, and can be found here.

All reports: All HQIP-commissioned reports can be accessed via our dedicated reports webpage. Stay up to date: Join our mailing list to receive notifications when new reports are published.

HQIP a finalist for three UK National Go Awards

7 Apr 2025

HQIP is delighted to be a finalist in three categories at the UK National Go Awards, taking place 21 May 2025: Best Procurement Team, Best Procurement Delivery, and Next Generation.

The awards ceremony celebrates the very best procurement achievements from across the UK’s public, private and third sector organisations. The Best Procurement Team nomination recognises HQIP’s unique approach to value-based procurement, combining expertise in procurement, patient engagement and quality improvement. It also notes the support that HQIP’s procurement specialists offer to other organisations, helping them to improve the value and outcomes of their procurement. The Best Procurement Delivery nomination focuses on the creation of the National Cancer Audit Collaborating Centre (NATCAN) to host all NHS national cancer audits. HQIP proposed an innovative umbrella approach to tendering, rather than commissioning individual projects.  NATCAN has made excellent progress in the two and a half years since the start of contract, enabling the NHS to identify and address areas of variation in patient care. Jon Williams, Senior Procurement Manager at HQIP, is also a finalist in the Next Generation award category, recognising the tenacity and innovation that he has brought to his role since joining the organisation in 2021 and his commitment to social value. Judith Hughes, Associate Director of Procurement at HQIP, comments: “I am proud that our thoughtful, value-based approach to procurement has been recognised by the Go Awards. We believe that integrating patient input into procurement can be transformative in driving greater value across the supply chain. That’s why we embed patient voice not only through our own commissioning, but also support and inspire other healthcare organisations to do the same.”

Our specialist healthcare procurement team provide:

  • Expert consultancy and bespoke training to embed quality, value, and patient voice into procurement
  • Flexible resourcing, from needs definition to contract award
  • Stakeholder, patient, and supplier engagement to shape procurement strategies and improve outcomes
Find out more about our Procurement+ approach or contact the team directly on workwithus@hqip.org.uk

The value of audit in identifying health inequalities

6 Apr 2025

Multiple inequalities in diagnosis and treatment are identified by the National Prostate Cancer Audit (NPCA)

What has the NPCA found?

The NPCA’s most recent State of the Nation report, published in January 2025, included a section which focused on inequalities in prostate cancer diagnosis and treatment. More specifically socioeconomic, demographic and ethnic differences between people diagnosed with prostate cancer between 2020 and 2023 in England. What they found showed that the inequalities identified in previous studies persist. Here they explain more… Inequalities at diagnosis: 90% of men diagnosed with prostate cancer had their ethnicity recorded and of these 90% were white, 5% Black and 2.4% Asian. 84% of men diagnosed with prostate cancer were between 50 and 79 years old and 24% lived in the least deprived areas. When adjusting for the size of the male population, white, Black or Asian, the Black population has the largest number of new diagnoses compared to the white and Asian groups, with 17 new diagnoses per 1000 men in black men aged 70-74. 79% of diagnoses had a stage recorded and of those, Black ethnic groups had a higher proportion of new diagnoses per 1000 men at stage 1 than other ethnic groups. We found stage 4 cancer to be the most common diagnosis in white men aged 85 years and over, which highlights late diagnosis in older men. These findings are limited by the low data completeness (49%) of stage for white men aged 85 years and over. Inequalities in treatment: 68% of black men aged 60 to 69 years with high-risk/locally advanced cancer received radical treatment compared to 82% white men of the same age and disease stage. We found a difference in radical treatment between least and most deprived areas, from 83% to 75% for men aged 60 to 69 years. A final finding was that treatment declines significantly from the age of 75 and that younger patients are more likely to receive treatment. In men with prostate cancer that has already spread at diagnosis, Black men were 24% less likely than white men to receive chemotherapy or additional hormone treatments. The same difference (24%) was observed when comparing men living in the most deprived areas than in the least. The special report on inequalities highlights a need for specific interventions to improve prostate cancer care so that it is equitable across all patient groups.

How can these findings be used to improve standards of care?

Results from the NPCA, in both our annual State of the Nation Reports and in our research articles, serve to highlight unwarranted differences in diagnoses and treatment at the population level which can be used as real-world evidence if national prostate cancer care guidelines are revised. Subsequent changes in wording would raise awareness of potential variation and provide support for patients to access equitable care at every step of their journey. This would ultimately lead to improved outcomes for people diagnosed with prostate cancer, regardless of when or where they were diagnosed and treated. There are many factors which influence the differences in prostate cancer care which we have described, whether alone or in combination, some of which may relate to patient choice and preference. These are complex in nature and different approaches by multiple groups and decision makers will be required to ensure men diagnosed with prostate cancer are offered and receive optimal care, ultimately resulting in improved outcomes. The NPCA, being commissioned by the English NHS and the Welsh Government, work closely with clinical leads to provide evidence of where improvements are needed and our stakeholders include professional bodies across the care pathway and colleges with influence on national level policy making.

What is the National Prostate Cancer Audit?

The National Prostate Cancer Audit is part of the National Cancer Audit Collaborating Centre (NATCAN), commissioned by Healthcare Quality Improvement Partnership (HQIP), on behalf of NHS England and the Welsh Government, as part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP).

What does the NPCA do?

The aims of the NPCA, and audits within NATCAN, are to provide cancer services in England and Wales with regular updates on their performance against national standards (when these exist) and other providers, through annual and quarterly reports. This means that we can also evidence whether different patterns of care are seen in different trusts or health boards. By shining a light on these differences, the audits enable NHS services to reflect on their provision and identify changes needed in order to provide equitable access to treatments for all patients, regardless of where they present. The NPCA, and audits within NATCAN, don’t ‘collect’ clinical data, we receive it from the National Disease Registration Service (NDRS) in NHSE and the Wales Cancer Network in Public Health Wales, with whom we work to improve data completeness. We have access to information on the diagnosis, treatments and outcomes of all patients newly diagnosed with prostate cancer in England and Wales as recorded by the providers themselves. This includes staging, how the patient presented, what their health is like generally, and what procedures they underwent, including surgery, radiotherapy or if they received systemic treatment such as chemotherapy or hormonal treatment.

What are the aims of the NPCA?

The NPCA redefined the scope of its work in 2023 and alongside that, identified key Quality Improvement goals in 2024 which ensure patient benefit continues to be at the heart of the work of the audit. Among these, reducing variation in prostate cancer management among NHS providers and improving experience of care among men with prostate cancer.

How does the NPCA achieve this?

The NPCA summarises the information received from routine data collections and produces an annual report (since 2014) which provides a national picture of the state of prostate cancer care in England and Wales. This means we have been able to monitor variation and changes in prostate cancer care for over a decade and make targeted suggestions to providers and commissioners on how to improve care. The audit feeds back information and recommendations to each provider so that they can truly reach the clinicians who can act on it, through the use of local action plans. Since 2024, we also produce quarterly reports, and since April 2025, a data dashboard updated quarterly is available collating data quality of key items and one performance indicator. Prior research undertaken by the audit reported on variation in care by ethnicity, age, socioeconomic status, and geographic location such as our report on treatment of men with high-risk or locally advanced prostate cancer. This identified differences in receipt of treatment for black and socio economically more deprived men. Short reports in 2020 and 2022 separately highlighted variation in diagnosis and care by ethnicity, age and socioeconomic status, so a comprehensive update on these findings was warranted to be able to identify the reasons behind the variation. A research study published in April 2025, looking at the geographic, socioeconomic and demographic inequalities in the incidence of prostate cancer which has spread at time of diagnosis identified unwarranted variation in England (2018-2022). Key findings include:
  • Regional annual rates of prostate cancer diagnoses where it has already spread (metastatic) were found to vary between 4 and 7 per 100 000 men
  • Higher rates of metastatic prostate cancer were seen in regions with lower rates of prostate cancer diagnosis overall
  • Higher rate of metastatic prostate cancer and a lower rate of prostate cancer overall was also seen among men living in more deprived neighbourhoods
In the future, the NPCA will aim to monitor the incidence of prostate cancer which has already spread at time of diagnosis considering these findings. This would provide an opportunity to assess improvements in timely diagnosis (and the ensuing ramifications for national policy about screening and early detection) more thoroughly than by just reporting the proportion of men diagnosed with prostate cancer who have metastatic disease. The programme of research of the NPCA is embedded in the audit activities and is key to the NPCA’s aim to get a better understanding determinants of variation and propose ways to ensure men diagnosed with prostate cancer at any stage benefit from equitable care.

What else is the NPCA doing?

The NPCA will be running a quality improvement initiative aiming to improve rates of treatment for men diagnosed with prostate cancer that has spread. We have already found that older men and Black men (when compared to white men) are less likely to receive treatment during earlier stages of the disease. We hope to understand the barriers to treatment which exist and by working with our partners at local and national levels, propose recommendations which will improve care, and ultimately outcomes, for men diagnosed with prostate cancer that has spread. Further information – links:
  • National Prostate Cancer Audit (NPCA)
  • The National Cancer Audit Collaborating Centre (NATCAN).
This article was shared as part of Clinical Audit Awareness Week 2025. Have your say on #CAAW25: Feedback form.

Clinical Audit Awareness Week 2025: Lunch & Learn events – sign up now!

2 Apr 2025

We’re pleased to announce the return of our popular Lunch & Learn online events during Clinical Audit Awareness Week 2025 (#CAAW25, 2nd – 6th June)! These sessions will take place daily from 12:30 to 1:30 PM and will feature a different theme. Please note that attendees are required to register in advance for each event. Click the links below to sign up.
  • 2 June: Patient Safety – Effectively utilising clinical audit to prevent avoidable harm
  • 3 June: Patient & Public Involvement (PPI) – Effectively utilising clinical audit to improve health and care by involving, engaging and informing patients and the public
  • 4 June: Healthcare Inequalities – Effectively utilising clinical audit to address inequalities in health and care
  • 5 June: Influencing Change – Effectively utilising clinical audit to influence change
  • 6 June: Efficiencies – Effectively utilising clinical audit to make healthcare sustainable.
Keep an eye out for the speakers that will be announced over the next few weeks. We’ll also be sharing updates on other events and activities throughout April and May! Details of all activities, events and daily Lunch & Learns being planned by HQIP, NQICAN and other partners will be shared over the coming weeks – you can stay up-to-date using the following channels: Online: Details on how to get involved in the Clinical Audit Heroes Awards and the wider #CAAW25 campaign will be made available on both HQIP and N-QI-CAN’s websites, as it becomes available. Newsletter updates: We will share updates in HQIP’s monthly eBulletins, while N-QI-CAN will provide updates via their enewsletter and ‘Forum’ (National Network and Sharing Forum, NNSF). Social media: You can also follow HQIP and N-QI-CAN on X, and HQIP’s LinkedIn, where information will be posted (look out for and use #CAAW25).

Benchmarking data available: National Ophthalmology Database Audit

2 Apr 2025

The National Ophthalmology Database Audit is the latest dataset to be published on the National Clinical Audit Benchmarking (NCAB) website. This data was updated on NCAB 12 February 2025 from the NODA report 2023 published on 2 May 2024 covering data from 1 April 2022 to 31 March 2023.

NCAB is an online portal, hosted by HQIP, which provides access to national audit performance data. Users do not need to register, and can access audit benchmarked data searchable by speciality, Trust, hospital or unit. For all datasets currently published, go to the NCAB site.

Latest news: March 2025 eBulletin

27 Mar 2025

March’s edition of HQIP’s eBulletin is available now. It features the most recent clinical audit and quality improvement updates, including:
  • Latest report on paediatric diabetes
  • Benchmarking data published (NCAB)
  • The Big ‘C’ – Collaboration
  • Clinical Audit Heroes Awards – NOW OPEN and Lunch & Learn events
  • New version of The Directory for 2025-26
  • Case study: Embedding patient voice in procurement
  • HQIP-commissioned maternity data used in research paper
Read the eBulletin here.
Don’t forget to sign up: Keep up to date with our latest news, events and work programmes by subscribing to our mailing list today. You can also follow us on LinkedIn and X: @HQIP

New resource published March 2025

13 Mar 2025

We are pleased to announce that the following new resource from HQIP-commissioned audits and programmes has been published. It includes an infographic, data and recommendations to support quality improvement:
  • Paediatric diabetes: care and outcomes 20234/24 report – National Paediatric Diabetes Audit (NPDA)

All reports: All HQIP-commissioned reports can be accessed via our dedicated reports webpage. Stay up to date: Join our mailing list to receive notifications when new reports are published.

Clinical Audit Awareness Week 2025 – Launch event recap

12 Mar 2025

Thank you to everyone who attended the online launch event on 12 March for Clinical Audit Awareness Week 2025 (#CAAW25), which will take place 2-6 June 2025! We were delighted to welcome over 200 attendees who joined us to hear the speakers – Chris Gush (HQIP CEO), Professor Danny Keenan (HQIP Medical Director), and Vicky Patel (N-QI-CAN Chair) – share valuable insights on the role of clinical audit and quality improvement in driving change and improving patient care. They also provided information on how to get involved in this year’s #CAAW25 campaign and Clinical Audit Heroes Awards.

Clinical Audit Heroes Awards 2025 categories & #CAAW25 Lunch & Learn events

During the launch event, we announced the five categories for the Clinical Audit Heroes Awards 2025, which will open on 27 March and close on 27 April:
  1. Patient Safety
  2. Patient & Public Involvement (PPI)
  3. Healthcare Inequalities
  4. Influencing Change
  5. Efficiencies
Further details, including the criteria for each category, will be announced in the week beginning 24 March 2025. We also announced the dates and themes for each of the online Lunch & Learn events taking place daily from 12:30 – 1:30 pm during #CAAW25 (2-6 June), where we’ll announce the awards winners. To find out more about the awards, Lunch & Learn events, and key dates and activities, head over to the Clinical Audit Awareness Week and Clinical Audit Heroes Awards webpages.

Catch up on the launch event

Missed the event or want to revisit the presentations? You can view the presentation slides here and watch the full launch event recording.

Get involved

Remember, if you plan to host your own #CAAW25 events and activities within your organisation, there is a free promotional toolkit available to support you! Stay tuned for further updates on our dedicated #CAAW25 webpage. We look forward to celebrating excellence in clinical audit and quality improvement with you!

Clinical Audit Heroes Awards 2025 – criteria

12 Mar 2025

It’s time to get ready to enter Clinical Audit Heroes Awards 2025 – part of Clinical Audit Awareness Week (#CAAW25)! We’re thrilled to announce that the judging and eligibility criteria are NOW LIVE for all five Clinical Audit Heroes Awards categories. The awards, which are run in collaboration with N-QI-CAN, will open for nominations on Thursday 27th March and close on Sunday 27th April 2025 (23:59). Now is your chance to showcase your project on clinical audit and quality improvement, and gain recognition for the difference you’re making. To find out more about the criteria and how to enter each award, click the links below:

New for 2025: Extra commendations!

In addition to these main categories, we’re also introducing two brand-new commendations for 2025: Each nomination form for the five main categories will include optional questions for those wishing to be considered for these extra commendations. You can simply opt in for these additional commendations by completing these optional questions when submitting your nomination(s). Winners will be announced during Clinical Audit Awareness Week (2nd – 6th June) at our daily Lunch & Learn online events. Full details and links to register for the Lunch & Learn events are now available on the dedicated  Clinical Audit Heroes Awards 2025 webpage. You can also follow updates on the Clinical Audit Awareness Week main page, on social media (HQIP and N-QI-CAN on X and LinkedIn) using the hashtag #CAAW25, and by signing up to HQIP’s monthly eBulletins. We look forward to celebrating the power of clinical audit and quality improvement in healthcare with you all.

Embedding patient voice in procurement case study

10 Mar 2025

HQIP manages a complex national clinical audit and outcome review programme, funded by NHS England and the Welsh government. Through rigorous specification-driven commissioning, HQIP facilitates the effective measurement of the quality of care and outcomes across a wide range of specialties. The programme supports clinical pathway improvement and reduces variability from evidence-based standards of care – improving outcomes for patients. Over many years, HQIP has refined a process that ensures that patient, carer and public engagement is embedded throughout this commissioning process.

This case study outlines:

  • The approach we took to embedding patient and public involvement (PPI) systematically in all projects commissioned
  • Examples of the impact that this has had
The case study can be viewed by clicking the button below: [button url=”https://www.hqip.org.uk/wp-content/uploads/2025/03/Case-study-Embedding-patient-voice-into-complex-procurement.pdf” target=”self”]Case study: Embedding patient voice into complex procurement[/button]  

How HQIP could help you

As a not-for-profit and trusted partner of the NHS, we understand complex healthcare challenges and take a patient-focused, evidence-informed approach to providing high quality solutions. So whether an organisation needs support with patient engagement, transformation strategy, improvement training, or value-based procurement support, we can help – with proven expertise across multiple areas of quality improvement. Contact our expert team for a free, no obligation conversation: workwithus@hqip.org.uk

New study uses HQIP-commissioned data to identify ‘recurring red flags’ in maternity

7 Mar 2025

A powerful new retrospective study on perinatal mortality has used reports from MBRRACE-UK, commissioned by HQIP on behalf of NHS England, to identify the maternity services that are most consistently reporting higher-than-average deaths in England. Published in February 2025 in the Journal of Public Health, this paper compares MBRRACE-UK perinatal mortality surveillance reports from 2015–21 with EPM rates for births occurring in 124 hospital trusts in England between 2013 and 2019. It identifies 23 (18.5% of 124) ‘red flag’ trusts most consistently falling into MBRRACE-UK red and amber bands, finding that seven trusts reported higher-than-average deaths in all seven years. With further findings considered within the context of contemporary inquiries, inspections, investigations and other outcome measures, this study concludes by stating that further research is needed to examine the reasons for the geographic proximity of most ‘red flag’ trusts, including any potential conflict around measures of clinical performance.
“Understanding how to react to data is the most important thing,” Adam Sewell-Jones, Executive Director of Improvement, NHS Improvement  
Studies such as this highlight the critical importance of data from outcome reviews, clinical audits and registries, such as the National Clinical Audit and Patient Outcomes Programme (NCAPOP) commissioned by HQIP on behalf of NHS England, in improving healthcare and, in turn, saving and improving lives.

Read the study in full

P McDonagh Hull, T Boulton, B Lashewicz, Recurring red flags: a retrospective study of MBRRACE-UK Perinatal Mortality Surveillance (2015–21) to identify maternity services most consistently reporting higher-than-average deaths, Journal of Public Health, 2025, fdaf019: https://doi.org/10.1093/pubmed/fdaf019. Copyright/access rights: Journal of Public Health, Oxford University Press.

Perinatal mortality surveillance report (MBRRACE-UK)

Published July 2024 Based on UK wide data for babies born in 2022, this report states that the most common causes of stillbirth and neonatal death were unchanged, finding that congenital anomalies contributed to 17% of deaths. It also includes the following key findings: • Stillbirth rates decreased across the UK in 2022, but neonatal mortality increased • There was wide variation in neonatal mortality rates • Stillbirth and neonatal mortality rates decreased in almost all gestational age groups • Inequalities in mortality rates by deprivation and ethnicity remain. Read in full

Further information

MBRRACE-UK is part of the Maternal, Newborn and Infant Clinical Outcome Review Programme (MNI-CORP), established to identify avoidable deaths so that the lessons learned can be used to prevent similar cases in the future, leading to improvements in maternal and newborn care for all mothers and babies.
Almost one in 100 UK births leads to a stillbirth or newborn death and up to 100 women die each year during or just after pregnancy
Further MBRRACE data and reports: • MBRRACE-UK reports on the HQIP website (scroll to the bottom of the page for all reports). MBRRACE-UK/MNI-CORP is part of a wider programme of audits and outcome reviews, commissioned by HQIP (NCAPOP) on a range of clinical disciplines, from asthma to vascular care: • All HQIP-commissioned reports.

My data, my health

6 Mar 2025

The importance of data sharing from a patient perspective

At HQIP, we have long-since advocated the value of data and patient voice in delivering evidence-informed healthcare improvement. But don’t just take our word for it. Find out what patients think in this exclusive interview with two public members of HQIP’s Data Access Request Group (DARG), which considers requests to re-use the healthcare data commissioned by HQIP.

Healthcare data is viewed as a gift by those considering access to it”

As commissioner of the National Clinical Audit and Patient Outcome Programme (NCAPOP), HQIP is responsible for the largest clinical audit programme of its type in the UK. This work results in an enormous amount of invaluable data that is used by healthcare providers to deliver targeted improvements. However, we also have a duty to re-use this data to bring about even greater public benefit where relevant, and so we run a stringent process to consider access requests from service planning, research and other similar projects. Being responsible for such data is something we do not take lightly. As such, we ensure that that any access granted is only given after the greatest of scrutiny. Critically, this involves members of the public, who add a unique – and vital – perspective to the decision-making process.

Since the data collected – whether access for secondary use is granted or not – belongs to patients, we have invited two public members of DARG to share their thoughts on what it means to them to be involved in this important work…

Let’s start with healthcare improvement more generally. It can be difficult to see the changes that are taking place to bring about data-informed improvements on a day-to-day basis, but do you have any experiences of this?

WENDY: When I was in hospital recently, I presented with symptoms that were initially put down to anxiety by the clinicians I saw. But one doctor came and said that they’d read a journal paper recently about how females can experience my health condition in atypical ways, and how these symptoms can be under reported. With this research in mind, they observed me, and determined that my symptoms did relate to my health condition. They were then able to identify the care that I needed. This, to me, was a clear example of how data and research are having a direct impact on healthcare.

If done correctly, there is absolutely a case for using healthcare data more”

PHIL: Over my 40 years in healthcare, I have seen many examples of how good data collection and evaluation has made a difference – though it can require determination to move away from ‘we’ve always done it this way’. In dementia care, for example, we’ve seen the introduction of Dementia Care Coordinators, a very positive change which came about by evaluating the experiences of those living with dementia. More recently, I’ve personally been involved in conversations with my doctor about a change in the approach to my medication, based on the latest research. So, yes, I am able to see the impact that data is having on healthcare.

In your view, what are the pros and cons of using healthcare data to inform research and improve care?

PHIL: Firstly, we need to remind ourselves that healthcare data belongs to patients. Then, the truth is that collecting data comes at a cost. These two factors mean that there is a moral obligation to use data for the benefit of patients wherever possible. However, I agree that this needs to be done carefully and safely.

Data provides a sound rationale for why we offer care in the way we do”

WENDY: Using data to inform care is incredibly important and powerful, but it needs to be approached with care. If done correctly, there is absolutely a case for using healthcare data more. In my experience, healthcare data is viewed as a gift by those considering access to it. Though I would like to see more case studies being shared with the public, to help us all to understand the stringent processes that are followed before releasing data for research, and the positive impact it has on patient care.

Why did you want to become involved in HQIP’s DARG; why is it important to you?

WENDY: I joined HQIP’s Service User Network (SUN) first, and was then offered the opportunity to join a short project to determine the feasibility of involving patients in decisions around access to data. We spoke to experts in patient engagement as well as other groups actively working with patients, to find out what worked well for them for use as inspiration for HQIP. When they advertised for public members to join DARG, I thought “I would love to be involved in that”, as I have real passion for health and data, and wanted to bring a patient perspective to the access process. For me, a big factor in patients getting involved is that they want to make a difference.

PHIL: As a frontline healthcare worker, I was involved in using clinical audit in its early days, and could see that data needs to form the basis for every single decision made. I joined DARG because I believe that data provides a sound rationale for why we offer care in the way we do, but I wanted to make sure that it is used primarily for the benefit of patients.

There is a moral obligation to use data for the benefit of patients wherever possible”

What does your involvement in DARG include; what do you do in practice?

WENDY: Regular meetings are held to decide on the latest tranche of applications for data. We are sent information in advance, which we review independently, from the perspective of a patient. Then, we actively participate in the meetings – which are pragmatic, thorough and methodical – to make decisions about whether to release the data or not. We very much work together as a group, collaborating alongside experts from a range of fields, to shine a light on each request from every possible viewpoint. All in all, I am confident that the decisions taken are solid and well thought through.

What works well, and what are the benefits of being involved?

WENDY: We are able to offer a unique viewpoint, asking ‘what is the benefit to the patient?’, learning every time we look at a request. We feel that we have had an impact on the process as well as the resultant research and, ultimately, healthcare. It’s like looking through a window, and then being invited to a seat at the table.

PHIL: I agree. Our discussions enable a robust decision to be made. There is no deference to status and everyone is happy to challenge, and that is very important. Patient involvement within HQIP’s data access process isn’t tokenistic. Our voice is heard, and our view is respected and accepted.

Conversely, what are the challenges and learning points?

WENDY: In hindsight, it would have been beneficial to trial taking part in a meeting, before joining DARG. It can be a little daunting as a non-clinical person but I remind myself that, if I’m asking, others may also be thinking the same thing. It’s important not to doubt yourself, as it’s vital to have a patient perspective in the room to ensure that the healthcare data available delivers maximum benefit for patients.

At HQIP, we couldn’t agree more. We see it as part of our mission to ensure that the data we commission is not only protected, but also put to good use. We know that researchers face complex and sometimes time-consuming barriers to accessing NHS data. Our aim is to help remove those barriers while upholding our responsibilities of patient confidentiality, data security and public trust. That means enabling researchers to ask better questions, produce stronger evidence, and ultimately influence how care is planned and delivered.

Meet our patient interviewees…Phil has over 40 years experience as a Registered Nurse. His career began in a NHS Acute Trust, where he specialised in Intensive Care before moving into hospital general management, spending the last 20 years as a Senior Lecturer at a UK University teaching Undergraduate healthcare students. He joined HQIP’s Data Access Request Group (DARG) in 2024 as a patient representative, following a diagnosis of Dementia with Lewy Bodies, a type of dementia caused by abnormal protein deposits in the brain. These deposits cause chemical changes in the brain, leading to problems with thinking, movement, balance and more, and makes daily activities increasingly difficult over time. Phil is also involved with the work of Dementia UK and the Alzheimers Society in advocating for those living with Dementia.Wendy is a parent, working full time as a Data Manager for a large private healthcare company.  She has a number of complex heart conditions, including a mechanical heart valve, a pacemaker and Atrial Fibrillation. She also had a stroke three years ago, caused by Atrial Fibrillation. Wendy says her health has given her a deeper appreciation for life, and she is driven by a passion to make the most of every day.  She joined HQIP’s Data Access Request Group (DARG) in 2024, and loves being able to represent the public in key decisions about health data.  She also volunteers for the British Heart Foundation and the European Society of Cardiology.

This article was shared as part of Clinical Audit Awareness Week 2025. Have your say on #CAAW25: Feedback form.

How to access HQIP-commissioned dataIf you are a researcher working in health services, clinical science, policy analysis or population health, we invite you to explore what the NCAPOP programme can offer. It is a valuable tool for those committed to evidence-informed care, and we are dedicated to supporting you in accessing it. To ensure transparency and responsible data use, HQIP has put in place a clear and structured application process. This requires you to:

  • Review the full Access to NCAPOP Data overview

  • Read detailed Information for Applicants

  • Complete the Data Access Request Form

  • Outline the intended use and public benefit of your project

  • Provide evidence of appropriate governance and ethical approvals.
  • Applications are considered by HQIP’s Data Access Request Group. This multidisciplinary panel includes HQIP staff, information governance experts, clinical advisors and public members. The group assesses requests against legal, ethical and strategic criteria to ensure that patient data is used appropriately, lawfully and securely.We encourage early engagement with our team. If you are unsure whether NCAPOP data is suitable for your project, or you would like to discuss your proposal informally before applying, we welcome a conversation. Contact us: datasharing@hqip.org.uk.

     

    Blog: Procurement Act 2023 leaves no room to ignore patient voice

    2 Mar 2025

    Judith Hughes, Associate Director of Procurement (MCIPS)

    On 24 February 2025, the Procurement Act 2023 (PA23) goes live amid a wider backdrop of significant change and pressure in UK health and care. Public sector procurement enters a new era – and for the NHS, the patient voice can no longer be ignored. Patient involvement has been very prominent in recent months, with increased social value obligations, PA23 requirements and Lord Darzi’s report. And this is only set to continue with the development of the 10 Year Health Plan for England, which aims to reduce the burden on NHS Trusts.

    What’s changing – and the opportunities this brings

    A key PA23 requirement is preliminary market engagement, a mandate for improving transparency and encouraging meaningful supplier interaction. The aim is to improve transparency and help ensure that providers understand the details of the tender exercise. This brings greater opportunities for the NHS to incorporate much needed change into the procurement process. Ignoring this isn’t just bad practice, it’s a missed opportunity for efficiency, innovation, and cost savings. Meaningful patient involvement leads to:
    • Smarter procurement – Solutions that better meet patient needs, encouraging adherence to treatments or uptake of new technologies.
    • Greater innovation – Diverse input leads to better, more relevant products, but also innovation of the clinical pathway itself.
    • NHS burden reduction – Better pathways of care mean better patient outcomes. Fewer failed procurements; saving money and resources.
    Involving internal stakeholders and patients as part of that will now not only be valuable – it will also be essential to make the preliminary market engagement meaningful. From 24 February, PA23 will bring a fundamental shift to NHS procurement. Against a backdrop of budgetary strain and rising patient dissatisfaction, one thing is clear: the NHS can no longer afford to ignore the patient voice in procurement.

    Why is the patient voice so important?

    Let’s look at the evidence around patient and public involvement and the need to have it built into procurement activities. Lord Darzi’s report on the English NHS highlighted the lack of the patient voice:
    1. Patient engagement. The patient voice is not loud enough.
    The NHS should aspire to deliver high quality care for all, all of the time. That not only means care that is safe and effective but that treats people with dignity, compassion and respect, making their experiences as positive as they can be. Yet patient satisfaction with services has declined and the number of complaints has increased, while patients are less empowered to make choices about their care. A familiar theme in inquiries into care failings has been patients’ concerns not being heard or acted upon. The NHS is paying out record sums in compensation payments for care failures, which now amount to nearly £3 billion or 1.7 per cent of the entire NHS budget.
    The 10 Year Health Plan for England, currently being drafted, will focus on three shifts that the Government, health service, and experts agree need to happen to create a health service fit for the future. These are:
    • Moving care from hospitals to communities
    • Making better use of technology
    • Focusing on preventing sickness, not just treating it
    The patient voice is a key driver for this plan to work – and procurement professionals play a pivotal role in achieving these goals. Involving the patients early in the design of the tendering process gives the opportunity to:
    • Have real life experiences help shape the requirement
    • Identify health inequalities
    • Understand what it is that patients want and the impact on them
    • Create an all-encompassing, fit for purpose specification
    • Highlight to providers how important the patient voice is, ensuring they design solutions with patients in mind
    • Improve outcomes
    HQIP have been involving patients and carers in commissioning for many years with great success. This has enabled improvements in relevance, patient-centeredness and efficiency; maximising both value for money and social value through better patient outcomes.

    How can you embed the patient voice under PA23 ?

    I recently attended the HFMA/HCSA Procurement Forum, where the speakers honed in on the biggest issue facing NHS procurement professionals today – how to release cost savings for the NHS, whilst still delivering a high quality service. Embedding the patient voice in service design significantly reduces the NHS burden by streamlining processes, enhancing efficiency, and driving cost savings. Prioritising patient-centred care not only improves outcomes but also optimises resource allocation, making healthcare delivery more sustainable. It also meets the needs under PA23 for robust market engagement, making it clear to potential providers that the patient is at the heart of the requirement. There are two key stages where patient engagement will now need to be an essential part of procurement with the launch of Procurement Act 23: Pre-Procurement Preparation – This helps you to fully understand and engage with the market, develop your strategy and plan the procurement process effectively. Whilst this is not a new step in the process, it does allow for greater engagement with internal stakeholders and the patient to really set out the objectives and aims of the requirement. Internal stakeholders are the subject matter experts, but they don’t always engage with the patient to be able to incorporate that much needed voice! Preliminary Market Engagement – This sets out the needs and benefits of your requirements. Including the patient voice as part of this will be a powerful tool to achieving a successful outcome. Potential providers will be armed with the right information to help them in their bid submission and understand how important the patient needs are.

    Need to improve patient engagement ? Act now – or risk falling behind!

    The NHS is under immense pressure to deliver cost savings without compromising quality. Ignoring the patient voice isn’t just poor procurement—it’s a failure in service design.
    Is your organisation ready for PA23?
    If not, we can help. HQIP’s procurement specialists have proven expertise in embedding the patient voice, ensuring compliance, efficiency, and long-term value. Doing this sustainably and valuably throughout the commissioning process can be complicated and time-consuming; it’s a journey that needs careful consideration at each stage. If the patient voice isn’t yet integrated into your organisation’s procurement, our expert team can help you understand what to prioritise and how to gain the support of key stakeholders – ensuring readiness for the new market engagement requirements of Procurement Act 23. HQIP is a not-for-profit, with a vision of improved health outcomes for all and a belief that patient and public involvement is imperative to healthcare improvement. We have healthcare procurement specialists with proven expertise of incorporating patient voice, working alongside our Patient and Carer Engagement team. This tailored expertise enables us to support projects that require deep NHS system knowledge, providing opportunities for long-term value and sustainable improvements that the large generalist consultancies often miss. Talk to us about how we can help youworkwithus@hqip.org.uk Or learn more about developing a strategic approach to embedding patient voice in procurement in this recent blog.